Circulating mitochondrial DAMPs cause inflammatory responses to injury.
Injury causes a systemic inflammatory response syndrome (SIRS) that is clinically much like sepsis. Microbial pathogen-associated molecular patterns (PAMPs) activate innate immunocytes through pattern recognition receptors. Similarly, cellular injury can release endogenous 'damage'-associated molecular patterns (DAMPs) that activate innate immunity. Mitochondria are evolutionary endosymbionts that were derived from bacteria and so might bear bacterial molecular motifs. Here we show that injury releases mitochondrial DAMPs (MTDs) into the circulation with functionally important immune consequences. MTDs include formyl peptides and mitochondrial DNA. These activate human polymorphonuclear neutrophils (PMNs) through formyl peptide receptor-1 and Toll-like receptor (TLR) 9, respectively. MTDs promote PMN Ca(2+) flux and phosphorylation of mitogen-activated protein (MAP) kinases, thus leading to PMN migration and degranulation in vitro and in vivo. Circulating MTDs can elicit neutrophil-mediated organ injury. Cellular disruption by trauma releases mitochondrial DAMPs with evolutionarily conserved similarities to bacterial PAMPs into the circulation. These signal through innate immune pathways identical to those activated in sepsis to create a sepsis-like state. The release of such mitochondrial 'enemies within' by cellular injury is a key link between trauma, inflammation and SIRS.
Zhang
Qin
Q
Department of Surgery, Division of Trauma, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA.
Raoof
Mustafa
M
Chen
Yu
Y
Sumi
Yuka
Y
Sursal
Tolga
T
Junger
Wolfgang
W
Brohi
Karim
K
Itagaki
Kiyoshi
K
Hauser
Carl J
CJ
D055371:Acute Lung Injury / Q000276:immunology / Q000473:pathology; D000818:Animals; D020013:Calcium Signaling; D002478:Cells, Cultured; D018899:CpG Islands / Q000276:immunology; D004272:DNA, Mitochondrial / Q000097:blood / Q000276:immunology; D005269:Femur / Q000293:injuries; D050723:Fractures, Bone / Q000276:immunology / Q000473:pathology; D006801:Humans; D007113:Immunity, Innate / Q000276:immunology; D008099:Liver / Q000276:immunology / Q000293:injuries / Q000473:pathology; D008297:Male; D008928:Mitochondria / Q000276:immunology* / Q000378:metabolism*; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D018482:Muscle, Skeletal / Q000276:immunology / Q000473:pathology; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000276:immunology / Q000378:metabolism; D009504:Neutrophils / Q000201:enzymology / Q000276:immunology / Q000378:metabolism; D010766:Phosphorylation; D051381:Rats; D017207:Rats, Sprague-Dawley; D044042:Receptors, Formyl Peptide / Q000378:metabolism; D018805:Sepsis / Q000276:immunology / Q000378:metabolism / Q000382:microbiology; D018746:Systemic Inflammatory Response Syndrome / Q000097:blood / Q000150:complications* / Q000276:immunology* / Q000473:pathology; D051217:Toll-Like Receptor 9 / Q000378:metabolism; D014947:Wounds and Injuries / Q000097:blood / Q000150:complications* / Q000276:immunology* / Q000473:pathology
D004272:DNA, Mitochondrial; D044042:Receptors, Formyl Peptide; C495371:TLR9 protein, human; D051217:Toll-Like Receptor 9; D009240:N-Formylmethionine Leucyl-Phenylalanine; D020928:Mitogen-Activated Protein Kinases